These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 12182262)

  • 1. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
    Kaplan EM
    Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    Entsuah AR; Huang H; Thase ME
    J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
    Rush AJ; Trivedi MH; Wisniewski SR; Stewart JW; Nierenberg AA; Thase ME; Ritz L; Biggs MM; Warden D; Luther JF; Shores-Wilson K; Niederehe G; Fava M;
    N Engl J Med; 2006 Mar; 354(12):1231-42. PubMed ID: 16554525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
    Whyte EM; Basinski J; Farhi P; Dew MA; Begley A; Mulsant BH; Reynolds CF
    J Clin Psychiatry; 2004 Dec; 65(12):1634-41. PubMed ID: 15641868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials.
    Einarson TR; Arikian SR; Casciano J; Doyle JJ
    Clin Ther; 1999 Feb; 21(2):296-308. PubMed ID: 10211533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
    Stahl SM; Entsuah R; Rudolph RL
    Biol Psychiatry; 2002 Dec; 52(12):1166-74. PubMed ID: 12488062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors.
    Sáiz-Ruiz J; Ibáñez A; Díaz-Marsá M; Arias F; Padín J; Martín-Carrasco M; Montes JM; Ferrando L; Carrasco JL; Martín-Ballesteros E; Jordá L; Chamorro L
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Oct; 26(6):1129-34. PubMed ID: 12452535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK; Kruzikas DT; McLaughlin TP
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder.
    Silverstone PH; Salinas E
    J Clin Psychiatry; 2001 Jul; 62(7):523-9. PubMed ID: 11488362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
    Schatzberg A; Roose S
    Am J Geriatr Psychiatry; 2006 Apr; 14(4):361-70. PubMed ID: 16582045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
    Silverstone PH; Ravindran A
    J Clin Psychiatry; 1999 Jan; 60(1):22-8. PubMed ID: 10074873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
    Mallick R; Chen J; Entsuah AR; Schatzberg AF
    J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies.
    Thase ME; Shelton RC; Khan A
    J Clin Psychopharmacol; 2006 Jun; 26(3):250-8. PubMed ID: 16702889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample.
    Vitiello B; Emslie G; Clarke G; Wagner KD; Asarnow JR; Keller MB; Birmaher B; Ryan ND; Kennard B; Mayes TL; DeBar L; Lynch F; Dickerson J; Strober M; Suddath R; McCracken JT; Spirito A; Onorato M; Zelazny J; Porta G; Iyengar S; Brent DA
    J Clin Psychiatry; 2011 Mar; 72(3):388-96. PubMed ID: 21208583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.